9 / 36
100
0
21
24
18
15
12
9
6
3
0
50
Months
Patients without ≥50%
decrease
in PSA (%)
Bicalutamide
Enzalutamide
Enzalutamide, n
184
159
131
107
86
71
52
33
21
Bicalutamide, n
191
133
85
61
44
30
13
7
4
HR=7.0
(95% CI: 4.8–10.2)
p<0.0001
Median 2.8 months
Enzalutamide rapidly got patients’
PSA under control compared with bicalutamide
Median NR
Shore ND, et al. Lancet Oncol 2016